|
SG11201505858VA
(en)
|
2013-01-28 |
2015-09-29 |
St Jude Childrens Res Hospital |
A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
|
|
AU2014386824B2
(en)
*
|
2013-03-15 |
2019-05-09 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
EP3789487A1
(en)
*
|
2013-04-03 |
2021-03-10 |
Memorial Sloan Kettering Cancer Center |
Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
|
|
EP3858379A1
(en)
|
2013-11-21 |
2021-08-04 |
Autolus Limited |
Cell
|
|
EP3805371A1
(en)
|
2014-05-15 |
2021-04-14 |
National University of Singapore |
Modified natural killer cells and uses thereof
|
|
CA2967222C
(en)
*
|
2014-11-12 |
2023-10-31 |
Rinat Neuroscience Corp. |
Inhibitory chimeric antigen receptors
|
|
EP3227323B1
(en)
|
2014-12-03 |
2020-08-05 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
|
HRP20240357T1
(hr)
|
2014-12-24 |
2024-06-07 |
Autolus Limited |
Stanica
|
|
US10626372B1
(en)
|
2015-01-26 |
2020-04-21 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
CA2977106A1
(en)
*
|
2015-02-27 |
2016-09-01 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
|
|
WO2016179319A1
(en)
*
|
2015-05-04 |
2016-11-10 |
Cellerant Therapeutics, Inc. |
Chimeric antigen receptors with ctla4 signal transduction domains
|
|
EP3770168A1
(en)
|
2015-05-18 |
2021-01-27 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
GB201509413D0
(en)
|
2015-06-01 |
2015-07-15 |
Ucl Business Plc |
Fusion protein
|
|
US11242375B2
(en)
|
2015-09-04 |
2022-02-08 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
|
US20180291080A1
(en)
*
|
2015-09-28 |
2018-10-11 |
Trustees Of Dartmouth College |
Chimeric antigen receptor, regulatory cells and methods of use
|
|
US12642852B1
(en)
|
2015-11-04 |
2026-06-02 |
Fate Therapeutics, Inc. |
Genomic engineering of pluripotent cells
|
|
CN122146606A
(zh)
|
2015-11-04 |
2026-06-05 |
菲特治疗公司 |
用于诱导造血细胞分化的方法和组合物
|
|
EP3377523A4
(en)
*
|
2015-11-19 |
2019-06-19 |
The Regents of The University of California |
CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
|
|
CN109072194B
(zh)
|
2015-12-09 |
2022-12-27 |
纪念斯隆-凯特林癌症中心 |
免疫细胞组合物及其使用方法
|
|
EP3408671B1
(en)
|
2016-01-25 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Methods for assaying t-cell dependent bispecific antibodies
|
|
CN105567640A
(zh)
*
|
2016-01-27 |
2016-05-11 |
苏州佰通生物科技有限公司 |
一种嵌合抗原受体脂肪干细胞及其制备方法
|
|
AU2017240233B2
(en)
*
|
2016-03-31 |
2022-07-14 |
University Of Southern California |
A highly sensitive and specific luciferase based reporter assay for antigen detection
|
|
CN109414512A
(zh)
|
2016-04-22 |
2019-03-01 |
科济生物医药（上海）有限公司 |
用于细胞免疫疗法的组合物和方法
|
|
EP3465203B1
(en)
*
|
2016-05-25 |
2026-03-18 |
The Council of the Queensland Institute of Medical Research |
Methods of immunotherapy
|
|
CN105950561A
(zh)
*
|
2016-05-26 |
2016-09-21 |
江苏杰晟生物科技有限公司 |
一种靶向乳腺癌干细胞的双特异性嵌合抗原受体基因修饰的t淋巴细胞的制备方法及其产品
|
|
WO2017210689A1
(en)
*
|
2016-06-03 |
2017-12-07 |
Memorial Sloan-Kettering Cancer Center |
Adoptive cell therapies as early treatment options
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
GB201614162D0
(en)
*
|
2016-08-18 |
2016-10-05 |
Polytherics Ltd |
Antibodies, uses thereof and conjugates thereof
|
|
CA3034691A1
(en)
|
2016-08-30 |
2018-03-08 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use for treating viral and other infections
|
|
MX2019003462A
(es)
*
|
2016-09-28 |
2019-08-16 |
Gavish Galilee Bio Appl Ltd |
Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer.
|
|
BR112019007100A2
(pt)
|
2016-10-07 |
2019-06-25 |
Tcr2 Therapeutics Inc |
composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
|
|
CN107988164B
(zh)
|
2016-10-26 |
2020-07-07 |
阿思科力(苏州)生物科技有限公司 |
一种pd-1 car nk-92细胞及其制备方法与应用
|
|
EP3315511A1
(en)
*
|
2016-10-29 |
2018-05-02 |
Miltenyi Biotec GmbH |
Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens
|
|
CN110177803A
(zh)
|
2016-11-22 |
2019-08-27 |
T细胞受体治疗公司 |
用于使用融合蛋白进行tcr重新编程的组合物和方法
|
|
CN108204958A
(zh)
*
|
2016-12-19 |
2018-06-26 |
伊缪泰普有限公司 |
结合测定
|
|
JP7078937B2
(ja)
*
|
2016-12-21 |
2022-06-01 |
ダンマークス テクニスク ユニバーシテット |
免疫細胞を操作するための抗原提示足場
|
|
WO2018124766A2
(ko)
*
|
2016-12-28 |
2018-07-05 |
주식회사 녹십자랩셀 |
키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
|
|
AU2018231190B2
(en)
*
|
2017-03-08 |
2023-05-25 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
|
MX2019011570A
(es)
|
2017-03-27 |
2019-11-18 |
Nat Univ Singapore |
Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
|
|
CN117363636A
(zh)
|
2017-03-27 |
2024-01-09 |
新加坡国立大学 |
一种编码嵌合受体的多核苷酸
|
|
CN109097402B
(zh)
*
|
2017-03-31 |
2021-09-07 |
国健呈诺生物科技(北京)有限公司 |
一种重组载体CAR-CD244-antiCD19的制备方法
|
|
JP2020517259A
(ja)
*
|
2017-04-19 |
2020-06-18 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
操作された抗原受容体を発現する免疫細胞
|
|
GB201707779D0
(en)
*
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
EP3631468A1
(en)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
|
PL3688155T3
(pl)
|
2017-09-28 |
2023-09-11 |
Immpact-Bio Ltd. |
Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
|
|
CN109593721B
(zh)
*
|
2017-09-30 |
2022-11-01 |
亘喜生物科技（上海）有限公司 |
具有自杀基因开关的靶向人间皮素的工程化免疫细胞
|
|
GB201717524D0
(en)
|
2017-10-25 |
2017-12-06 |
Autolus Ltd |
Vectors
|
|
KR102774451B1
(ko)
|
2017-11-14 |
2025-02-28 |
앱클론(주) |
항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
|
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
WO2019111249A1
(en)
*
|
2017-12-05 |
2019-06-13 |
The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center |
T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof
|
|
US12139522B2
(en)
|
2017-12-05 |
2024-11-12 |
The Medical Research Infrastructure And Heal Serviced Fund Of The Tel Aviv Medecal Center |
T-cells comprising two different chimeric antigen receptors and uses thereof
|
|
GB201721802D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Almac Discovery Ltd |
Ror1-specific antigen binding molecules
|
|
IL326873A
(en)
*
|
2017-12-29 |
2026-04-01 |
Memorial Sloan Kettering Cancer Center |
Enhanced chimeric antigen receptors and uses thereof
|
|
CN111867619A
(zh)
|
2018-01-03 |
2020-10-30 |
曲生物制品公司 |
过继性细胞治疗的先天寻靶
|
|
JP7360174B2
(ja)
|
2018-02-09 |
2023-10-12 |
ナショナル ユニヴァーシティー オブ シンガポール |
ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
|
|
CN109321530B
(zh)
*
|
2018-02-12 |
2021-03-12 |
华东师范大学 |
一种安全型嵌合抗原受体t细胞及其用途
|
|
WO2019165121A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses therof
|
|
US12441787B2
(en)
|
2018-04-02 |
2025-10-14 |
National University Of Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
EP3773588A4
(en)
*
|
2018-04-09 |
2022-01-19 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASES
|
|
CN110526976A
(zh)
*
|
2018-05-25 |
2019-12-03 |
深圳宾德生物技术有限公司 |
一种靶向psma的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
|
|
CN110526984A
(zh)
*
|
2018-05-25 |
2019-12-03 |
深圳宾德生物技术有限公司 |
一种靶向psma的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
|
|
WO2019242632A1
(en)
*
|
2018-06-19 |
2019-12-26 |
1§1Nanjing Legend Biotech Co., Ltd. |
Engineered cells and uses thereof
|
|
TW202016144A
(zh)
*
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
|
WO2020044239A1
(en)
|
2018-08-29 |
2020-03-05 |
National University Of Singapore |
A method to specifically stimulate survival and expansion of genetically-modified immune cells
|
|
BR112021006100A2
(pt)
|
2018-09-28 |
2021-07-20 |
Immpact-Bio Ltd. |
métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
|
|
EP3856769A4
(en)
*
|
2018-09-28 |
2022-08-17 |
Memorial Sloan Kettering Cancer Center |
IMMUNOREACTIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
US12624086B2
(en)
|
2018-10-31 |
2026-05-12 |
Mayo Foundation For Medical Education And Research |
Materials and methods for treating cancer
|
|
US12264189B2
(en)
|
2018-10-31 |
2025-04-01 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US12257286B2
(en)
|
2018-10-31 |
2025-03-25 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US12466892B2
(en)
|
2018-11-08 |
2025-11-11 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
CN113226340A
(zh)
|
2018-11-26 |
2021-08-06 |
恩卡尔塔公司 |
同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
|
|
CN109517799B
(zh)
*
|
2018-11-30 |
2022-07-26 |
北京美康基免生物科技有限公司 |
一种基于cd19和cd22的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
ES3051182T3
(en)
|
2019-01-23 |
2025-12-26 |
Miltenyi Biotec Bv & Co Kg |
A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
|
|
CA3130489A1
(en)
*
|
2019-02-18 |
2020-08-27 |
Memorial Sloan-Kettering Cancer Center |
Combinations of multiple chimeric antigen receptors for immunotherapy
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
JP7711945B2
(ja)
|
2019-04-30 |
2025-07-23 |
センティ バイオサイエンシズ インコーポレイテッド |
キメラ受容体及びその使用方法
|
|
CN110592014A
(zh)
*
|
2019-08-14 |
2019-12-20 |
广东美赛尔细胞生物科技有限公司 |
一种在nk细胞治疗中免辐照体外体内持续去除饲养细胞的方法
|
|
EP4017510A4
(en)
*
|
2019-08-20 |
2023-11-22 |
Senti Biosciences, Inc. |
CHIMERIC INHIBITOR RECEPTOR
|
|
WO2021041920A1
(en)
*
|
2019-08-28 |
2021-03-04 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
WO2021044213A2
(en)
*
|
2019-09-05 |
2021-03-11 |
Migal-galilee Research Institute Ltd. |
Blocking chimeric antigen receptors for prevention of undesired activation of effector and regulatory immune cells
|
|
US20220372092A1
(en)
*
|
2019-10-18 |
2022-11-24 |
Board Of Regents, The University Of Texas System |
Hla-restricted vcx/y peptides and t cell receptors and use thereof
|
|
AU2020397170A1
(en)
*
|
2019-12-05 |
2022-07-21 |
Sanofi-Aventis U.S. Llc |
Formulations of anti-CD38 antibodies for subcutaneous administration
|
|
WO2021119489A1
(en)
|
2019-12-11 |
2021-06-17 |
A2 Biotherapeutics, Inc. |
Lilrb1-based chimeric antigen receptor
|
|
CN115066249A
(zh)
|
2020-02-04 |
2022-09-16 |
美天施生物科技有限两合公司 |
表达用于感测可溶性抗原的适体嵌合抗原受体的免疫细胞
|
|
WO2021168317A1
(en)
*
|
2020-02-20 |
2021-08-26 |
Senti Biosciences, Inc. |
Inhibitory chimeric receptor architectures
|
|
CN111249314B
(zh)
*
|
2020-03-03 |
2022-03-29 |
深圳未知君生物科技有限公司 |
人体共生菌群在提高肿瘤免疫治疗应答中的作用
|
|
CN115916250A
(zh)
*
|
2020-05-20 |
2023-04-04 |
美天施生物科技有限两合公司 |
用于治疗表达cd90和cd326的癌症的组合物和方法
|
|
US12286465B2
(en)
|
2020-05-28 |
2025-04-29 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
|
|
WO2022007784A1
(en)
*
|
2020-07-06 |
2022-01-13 |
Nanjing Legend Biotech Co., Ltd. |
Methods of reducing graft rejection of allogeneic cell therapy
|
|
US20230272039A1
(en)
|
2020-07-16 |
2023-08-31 |
Umoja Biopharma, Inc. |
Gated adapter targeting receptor
|
|
US20230257441A1
(en)
*
|
2020-08-13 |
2023-08-17 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating cancers
|
|
WO2022037323A1
(zh)
*
|
2020-08-19 |
2022-02-24 |
上海易慕峰生物科技有限公司 |
人源化抗体、嵌合抗原受体、核酸、载体、细胞及应用
|
|
WO2022040454A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
|
US11433100B2
(en)
|
2020-08-20 |
2022-09-06 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating ceacam positive cancers
|
|
EP4058474B1
(en)
|
2020-08-20 |
2024-05-08 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating egfr positive cancers
|
|
EP4097486A4
(en)
|
2020-08-20 |
2023-09-06 |
A2 Biotherapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER
|
|
US20220090015A1
(en)
|
2020-09-21 |
2022-03-24 |
A2 Biotherapeutics, Inc. |
Engineered immune cells with multiplex and localized activity
|
|
WO2022096664A1
(en)
|
2020-11-09 |
2022-05-12 |
Miltenyi Biotec B.V. & Co. KG |
Methods and compositions for eliminating engineered immune cells
|
|
CN116723861A
(zh)
|
2020-12-02 |
2023-09-08 |
上海复宏汉霖生物技术股份有限公司 |
抗GARP/TGFβ抗体及使用方法
|
|
CN114569708B
(zh)
*
|
2020-12-02 |
2023-07-04 |
四川大学华西医院 |
Nkg2d car-免疫细胞在抗衰老中应用
|
|
IL303269A
(en)
|
2020-12-03 |
2023-07-01 |
Century Therapeutics Inc |
Genetically engineered cells and uses thereof
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
EP4255454A4
(en)
*
|
2020-12-07 |
2025-01-08 |
The Johns Hopkins University |
NATURAL KILLER CELL ENGINEERING METHODS TO ENHANCE TUMOR TARGETING
|
|
TW202241935A
(zh)
|
2020-12-18 |
2022-11-01 |
美商世紀治療股份有限公司 |
具有可調適受體專一性之嵌合抗原受體系統
|
|
US20240082306A1
(en)
*
|
2021-02-03 |
2024-03-14 |
Bioheng Therapeutics Limited |
Novel chimeric antigen receptor and use thereof
|
|
IL304857A
(en)
|
2021-02-16 |
2023-10-01 |
A2 Biotherapeutics Inc |
Preparations and methods for treating HER2 POSITIVE cancer
|
|
CA3213040A1
(en)
*
|
2021-03-22 |
2022-09-29 |
Michel Sadelain |
Cd38 chimeric co-stimulating receptor and uses thereof
|
|
US20240390497A1
(en)
*
|
2021-09-15 |
2024-11-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions of chimeric antigen receptor (car) signaling molecules and uses thereof
|
|
WO2023057285A1
(en)
|
2021-10-06 |
2023-04-13 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
CN118488965A
(zh)
|
2021-12-17 |
2024-08-13 |
上海复宏汉霖生物技术股份有限公司 |
抗ox40抗体、多特异性抗体及其使用方法
|
|
AU2022411573A1
(en)
|
2021-12-17 |
2024-06-27 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-ox40 antibodies and methods of use
|
|
KR20240163119A
(ko)
|
2022-03-25 |
2024-11-18 |
상하이 헨리우스 바이오테크, 인크. |
항-msln 항체 및 사용 방법
|
|
WO2024078995A1
(en)
|
2022-10-15 |
2024-04-18 |
Miltenyi Biotec B.V. & Co. KG |
Transduction of gammadelta t cells with pseudotyped retroviral vectors
|
|
CN116785458A
(zh)
*
|
2023-02-14 |
2023-09-22 |
青岛大学 |
半滑舌鳎抗病蛋白shp-1基因的应用
|
|
CN116376844B
(zh)
*
|
2023-05-31 |
2023-08-11 |
四川大学华西医院 |
包含shp2 sh2结构域的靶向her2阳性肿瘤的car-t及制备方法和应用
|
|
CN119119191B
(zh)
*
|
2024-09-13 |
2025-04-01 |
渤海大学 |
一种海参肠多肽及其在制备胃部疾病药物中的应用
|